Peptonic Medical AB has secured a strong patent protection for Vagitocin® with coverage through 2032. The work with VagiVital® is ongoing.
– Use of Substances with Oxytocin Activity for Climateric/Menopausal Disorders.
– Use of Oxytocin for the Preparation of a Pharmaceutical Composition Against Cancer in Situ and Cervictis, only in USA.
– Novel Topical Composition of Oxytocin for use for Local Treatment of Vaginal Atrophy.
– A peptide to create Eustasis, only in USA.
We have filed a patent for the use of VagiVital® in climacteric disorders which is still pending. Two other filed patents, which cover oxytocin use in other indications, are also pending. We aim to file other additional patents in the area.
Vagitocin® is a proprietary trademark of Peptonic Medical AB and is registered in Europe, USA and Australia. VagiVital® is also a proprietary trademark of Peptonic Medical AB, at the moment approved throughout EU and in Norway. Work with extension of the countries is ongoing.